What is the current valuation of the Foot and Mouth Disease Vaccine Market?

The market valuation was 3.006 USD Billion in 2024. Read More

What is the projected market size for the Foot and Mouth Disease Vaccine Market by 2035?

The market is projected to reach 4.905 USD Billion by 2035. Read More

What is the expected CAGR for the Foot and Mouth Disease Vaccine Market during the forecast period 2025 - 2035?

The expected CAGR is 4.55% during the forecast period 2025 - 2035. Read More

Which livestock segments are included in the Foot and Mouth Disease Vaccine Market?

The livestock segments include Cattle, Goats, Sheep, and Pigs, with Cattle valued at 1.2 to 1.8 USD Billion. Read More

What types of vaccines are available in the Foot and Mouth Disease Vaccine Market?

The market includes Inactivated Vaccines, Attenuated Vaccines, and Recombinant Vaccines, with Inactivated Vaccines valued at 1.503 to 2.453 USD Billion. Read More

What are the primary application routes for Foot and Mouth Disease vaccines?

The primary application routes are Subcutaneous Injection, Intramuscular Injection, and Intranasal Route, with Intramuscular Injection valued at 1.5 to 2.3 USD Billion. Read More

What is the duration of immunity offered by Foot and Mouth Disease vaccines?

The duration of immunity varies, with Long-term (more than 24 months) vaccines valued at 0.901 to 2.095 USD Billion. Read More

Who are the key players in the Foot and Mouth Disease Vaccine Market?

Key players include Zoetis, Merck Animal Health, Boehringer Ingelheim, and Elanco Animal Health. Read More

How does the market for Foot and Mouth Disease vaccines compare across different livestock?

The market for Pigs is valued at 0.706 to 1.505 USD Billion, indicating a diverse valuation across livestock. Read More

What trends are expected to shape the Foot and Mouth Disease Vaccine Market in the coming years?

Trends may include increased investment in vaccine development and a focus on improving vaccine efficacy and delivery methods. Read More

Foot And Mouth Disease Vaccine Market

ID: MRFR/HC/25899-HCR

100 Pages

Rahul Gotadki

Last Updated: June 08, 2026

Foot and Mouth Disease Vaccine Market Research Report By Livestock (Cattle, Goats, Sheep, Pigs), By Vaccine Type (Inactivated Vaccines, Attenuated Vaccines, Recombinant Vaccines), By Application Route (Subcutaneous Injection, Intramuscular Injection, Intranasal Route), By Duration of Immunity (Short-term (less than 12 months), Medium-term (12-24 months), Long-term (more than 24 months)) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Livestock (USD Billion)
  1. 4.1.1 Cattle
  2. 4.1.2 Goats
  3. 4.1.3 Sheep
  4. 4.1.4 Pigs
2. 4.2 Healthcare, BY Vaccine Type (USD Billion)
  1. 4.2.1 Inactivated Vaccines
  2. 4.2.2 Attenuated Vaccines
  3. 4.2.3 Recombinant Vaccines
3. 4.3 Healthcare, BY Application Route (USD Billion)
  1. 4.3.1 Subcutaneous Injection
  2. 4.3.2 Intramuscular Injection
  3. 4.3.3 Intranasal Route
4. 4.4 Healthcare, BY Duration of Immunity (USD Billion)
  1. 4.4.1 Short-term (less than 12 months)
  2. 4.4.2 Medium-term (12-24 months)
  3. 4.4.3 Long-term (more than 24 months)
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Zoetis (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck Animal Health (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Boehringer Ingelheim (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Elanco Animal Health (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Vetoquinol (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Heska Corporation (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Ceva Santé Animale (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Indian Immunologicals Limited (IN)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Soochow Industrial Group (CN)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY LIVESTOCK
4. 6.4 US MARKET ANALYSIS BY VACCINE TYPE
5. 6.5 US MARKET ANALYSIS BY APPLICATION ROUTE
6. 6.6 US MARKET ANALYSIS BY DURATION OF IMMUNITY
7. 6.7 CANADA MARKET ANALYSIS BY LIVESTOCK
8. 6.8 CANADA MARKET ANALYSIS BY VACCINE TYPE
9. 6.9 CANADA MARKET ANALYSIS BY APPLICATION ROUTE
10. 6.10 CANADA MARKET ANALYSIS BY DURATION OF IMMUNITY
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY LIVESTOCK
13. 6.13 GERMANY MARKET ANALYSIS BY VACCINE TYPE
14. 6.14 GERMANY MARKET ANALYSIS BY APPLICATION ROUTE
15. 6.15 GERMANY MARKET ANALYSIS BY DURATION OF IMMUNITY
16. 6.16 UK MARKET ANALYSIS BY LIVESTOCK
17. 6.17 UK MARKET ANALYSIS BY VACCINE TYPE
18. 6.18 UK MARKET ANALYSIS BY APPLICATION ROUTE
19. 6.19 UK MARKET ANALYSIS BY DURATION OF IMMUNITY
20. 6.20 FRANCE MARKET ANALYSIS BY LIVESTOCK
21. 6.21 FRANCE MARKET ANALYSIS BY VACCINE TYPE
22. 6.22 FRANCE MARKET ANALYSIS BY APPLICATION ROUTE
23. 6.23 FRANCE MARKET ANALYSIS BY DURATION OF IMMUNITY
24. 6.24 RUSSIA MARKET ANALYSIS BY LIVESTOCK
25. 6.25 RUSSIA MARKET ANALYSIS BY VACCINE TYPE
26. 6.26 RUSSIA MARKET ANALYSIS BY APPLICATION ROUTE
27. 6.27 RUSSIA MARKET ANALYSIS BY DURATION OF IMMUNITY
28. 6.28 ITALY MARKET ANALYSIS BY LIVESTOCK
29. 6.29 ITALY MARKET ANALYSIS BY VACCINE TYPE
30. 6.30 ITALY MARKET ANALYSIS BY APPLICATION ROUTE
31. 6.31 ITALY MARKET ANALYSIS BY DURATION OF IMMUNITY
32. 6.32 SPAIN MARKET ANALYSIS BY LIVESTOCK
33. 6.33 SPAIN MARKET ANALYSIS BY VACCINE TYPE
34. 6.34 SPAIN MARKET ANALYSIS BY APPLICATION ROUTE
35. 6.35 SPAIN MARKET ANALYSIS BY DURATION OF IMMUNITY
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY LIVESTOCK
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY VACCINE TYPE
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY APPLICATION ROUTE
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY DURATION OF IMMUNITY
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY LIVESTOCK
42. 6.42 CHINA MARKET ANALYSIS BY VACCINE TYPE
43. 6.43 CHINA MARKET ANALYSIS BY APPLICATION ROUTE
44. 6.44 CHINA MARKET ANALYSIS BY DURATION OF IMMUNITY
45. 6.45 INDIA MARKET ANALYSIS BY LIVESTOCK
46. 6.46 INDIA MARKET ANALYSIS BY VACCINE TYPE
47. 6.47 INDIA MARKET ANALYSIS BY APPLICATION ROUTE
48. 6.48 INDIA MARKET ANALYSIS BY DURATION OF IMMUNITY
49. 6.49 JAPAN MARKET ANALYSIS BY LIVESTOCK
50. 6.50 JAPAN MARKET ANALYSIS BY VACCINE TYPE
51. 6.51 JAPAN MARKET ANALYSIS BY APPLICATION ROUTE
52. 6.52 JAPAN MARKET ANALYSIS BY DURATION OF IMMUNITY
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY LIVESTOCK
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY VACCINE TYPE
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY APPLICATION ROUTE
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY DURATION OF IMMUNITY
57. 6.57 MALAYSIA MARKET ANALYSIS BY LIVESTOCK
58. 6.58 MALAYSIA MARKET ANALYSIS BY VACCINE TYPE
59. 6.59 MALAYSIA MARKET ANALYSIS BY APPLICATION ROUTE
60. 6.60 MALAYSIA MARKET ANALYSIS BY DURATION OF IMMUNITY
61. 6.61 THAILAND MARKET ANALYSIS BY LIVESTOCK
62. 6.62 THAILAND MARKET ANALYSIS BY VACCINE TYPE
63. 6.63 THAILAND MARKET ANALYSIS BY APPLICATION ROUTE
64. 6.64 THAILAND MARKET ANALYSIS BY DURATION OF IMMUNITY
65. 6.65 INDONESIA MARKET ANALYSIS BY LIVESTOCK
66. 6.66 INDONESIA MARKET ANALYSIS BY VACCINE TYPE
67. 6.67 INDONESIA MARKET ANALYSIS BY APPLICATION ROUTE
68. 6.68 INDONESIA MARKET ANALYSIS BY DURATION OF IMMUNITY
69. 6.69 REST OF APAC MARKET ANALYSIS BY LIVESTOCK
70. 6.70 REST OF APAC MARKET ANALYSIS BY VACCINE TYPE
71. 6.71 REST OF APAC MARKET ANALYSIS BY APPLICATION ROUTE
72. 6.72 REST OF APAC MARKET ANALYSIS BY DURATION OF IMMUNITY
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY LIVESTOCK
75. 6.75 BRAZIL MARKET ANALYSIS BY VACCINE TYPE
76. 6.76 BRAZIL MARKET ANALYSIS BY APPLICATION ROUTE
77. 6.77 BRAZIL MARKET ANALYSIS BY DURATION OF IMMUNITY
78. 6.78 MEXICO MARKET ANALYSIS BY LIVESTOCK
79. 6.79 MEXICO MARKET ANALYSIS BY VACCINE TYPE
80. 6.80 MEXICO MARKET ANALYSIS BY APPLICATION ROUTE
81. 6.81 MEXICO MARKET ANALYSIS BY DURATION OF IMMUNITY
82. 6.82 ARGENTINA MARKET ANALYSIS BY LIVESTOCK
83. 6.83 ARGENTINA MARKET ANALYSIS BY VACCINE TYPE
84. 6.84 ARGENTINA MARKET ANALYSIS BY APPLICATION ROUTE
85. 6.85 ARGENTINA MARKET ANALYSIS BY DURATION OF IMMUNITY
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY LIVESTOCK
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY VACCINE TYPE
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION ROUTE
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY DURATION OF IMMUNITY
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY LIVESTOCK
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY VACCINE TYPE
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION ROUTE
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY DURATION OF IMMUNITY
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY LIVESTOCK
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY VACCINE TYPE
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION ROUTE
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY DURATION OF IMMUNITY
99. 6.99 REST OF MEA MARKET ANALYSIS BY LIVESTOCK
100. 6.100 REST OF MEA MARKET ANALYSIS BY VACCINE TYPE
101. 6.101 REST OF MEA MARKET ANALYSIS BY APPLICATION ROUTE
102. 6.102 REST OF MEA MARKET ANALYSIS BY DURATION OF IMMUNITY
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY LIVESTOCK, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY LIVESTOCK, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY VACCINE TYPE, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY VACCINE TYPE, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY APPLICATION ROUTE, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY APPLICATION ROUTE, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY DURATION OF IMMUNITY, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY DURATION OF IMMUNITY, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.2.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.2.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.3.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.3.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.3.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.4.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.4.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.4.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.5.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.5.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.5.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.6.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.6.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.6.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.7.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.7.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.7.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.8.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.8.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.8.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.9.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.9.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.9.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.10.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.10.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.10.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.11.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.11.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.11.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.12.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.12.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.12.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.13.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.13.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.13.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.14.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.14.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.14.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.15.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.15.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.15.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.16.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.16.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.16.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.17.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.17.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.17.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.18.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.18.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.18.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.19.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.19.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.19.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.20.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.20.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.20.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.21.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.21.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.21.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.22.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.22.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.22.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.23.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.23.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.23.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.24.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.24.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.24.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.25.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.25.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.25.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.26.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.26.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.26.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.27.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.27.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.27.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.28.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.28.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.28.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.29.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.29.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.29.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY LIVESTOCK, 2025-2035 (USD Billion)
  2. 7.30.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.30.3 BY APPLICATION ROUTE, 2025-2035 (USD Billion)
  4. 7.30.4 BY DURATION OF IMMUNITY, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Foot And Mouth Disease Vaccine Market Segmentation

Foot And Mouth Disease Vaccine Market By Livestock (USD Billion, 2025-2035)

Cattle
Goats
Sheep
Pigs

Foot And Mouth Disease Vaccine Market By Vaccine Type (USD Billion, 2025-2035)

Inactivated Vaccines
Attenuated Vaccines
Recombinant Vaccines

Foot And Mouth Disease Vaccine Market By Application Route (USD Billion, 2025-2035)

Subcutaneous Injection
Intramuscular Injection
Intranasal Route

Foot And Mouth Disease Vaccine Market By Duration of Immunity (USD Billion, 2025-2035)

Short-term (less than 12 months)
Medium-term (12-24 months)
Long-term (more than 24 months)

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”